Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Lemos, Claudia N C D ^a   Reis, Fernando M ^a   Pena, Guilherme N ^a   Silveira, Laila C ^a   Camargos, Aroldo F ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CYCLOPHOSPHAMIDE; GONADORELIN ANTAGONIST; PLACEBO; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GONADORELIN; HORMONE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREEDING; CONTROLLED STUDY; ESTRUS CYCLE; FEMALE; FEMALE FERTILITY; HISTOPATHOLOGY; MATING; NONHUMAN; OVARIAN RESERVE; OVARY FOLLICLE; PROESTRUS; PROGENY; RAT; VAGINA SMEAR; WISTAR RAT; ANIMAL; CELL COUNT; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE INFERTILITY; FERTILITY; NEOPLASM; OVARY; PREGNANCY; PREGNANCY RATE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COUNT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; INFERTILITY, FEMALE; NEOPLASMS; OVARY; PLACEBOS; PREGNANCY; PREGNANCY RATE; RATS; RATS, WISTAR;

EID: 77953975772     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-51     Document Type: Article

References (28)

1. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996, 11:1620-1626.
2. Maltaris T, Seufert R, Fischi F, Schaffrath M, Pollow K, Koelbl H, Dittrich R. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007, 130:148-155.
3. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv 2007, 62:58-72.
4. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y, RobisonSklar LL. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006, 98:890-896.
5. Zhang J, Tian Q, Zhou S. Clinical Pharmacology of Cyclophosphamide and Ifosfamide. Current Drug Ther 2006, 1:29-41.
6. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, Ozturk A. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril 2009, 30:30-36.
7. Tan SJ, Yeh Y, Shang W, Wua G, Liu J, Chen C. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: A mouse model. Eur J Obstet Gynecol Reprod Biol 2010, 12-16.
8. Sverrisdottir A, Nystedt M, Johansson H, FornanderSverrisdottir T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009, 117:561-567.
9. Megan EB, Clowse MEB, Behera MA, Anders CK, Copland S, Coffman C, Leppert PC, Bastian LA. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009, 18:311-319.
10. M.D. Anderson Cancer Center Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer NCT00429403. M.D. Anderson Cancer Center., http://clinicaltrials.gov/ct2/show/NCT00429403?term=NCT00429403
11. Gruppo Italiano Mammella Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery. Gruppo Italiano Mammella., http://clinicaltrials.gov/ct2/show/NCT00311636
12. Anglo Celtic Cooperative Oncology Group Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer S0230: NCT00427245. Anglo Celtic Cooperative Oncology Group., http://clinicaltrials.gov/ct2/show/NCT00427245
13. Southwest Oncology Group Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer OPTION: NCT00068601. Southwest Oncology Group., http://clinicaltrials.gov/ct2/results?term=nct00068601
14. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002, 13(Suppl 1):138-147.
15. Sharp CARM. The Laboratory Rat 1998, Edited by CRC Press Boca Ratton.
16. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani, Reissmann T, Krebs D, Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994, 9:788-791.
17. Schwahn M, Nagaraja NV, Derendorf H, Derendorf H. Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, sterone in rats and dogs. Pharm Res 2000, 17:328-335.
18. Letterie GS. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 2004, 19:831-837.
19. Montz FJ, Wolf AJ, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991, 51:2124-2126.
20. Smith BJ, Plowchalk DR, Sipes IG, Mattison DR. Comparison of random and serial sections in assessment of ovarian toxicity. Reprod Toxico 1991, 5:379-383.
21. Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, Cameron A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006, 21:2583-2592.
22. Imai A, Furui T, Yakamoto A. Preservation of female fertility during cancer treatment. Reproductive Medicine and Biology 2008, 7:11.
23. Imai A, Furui T, Sugiyama M, Tamaya T. Gonadotropin releasing hormone (GnRH) analogues in anticancer management: clinical applications and antiproliferative signaling. Curr Top Pharmacol 2002, 6:119-28.
24. Ghosha S, Misrob M, Dasa UB, Maitia R, Debnatha JM, Ghosha D. Effect of human chorionic gonadotrophin coadministration on ovarian steroidogenic and folliculogenic activities in cyclophosphamide treated albino rats. Reprod Toxicol 2001, 15:221-225.
25. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004, 19:1294-1299.
26. Ethics Committee of the American Society for Reproductive Medicine Fertility preservation and reproduction in cancer patients. Fertil Steril 2005, 83:1622-1628. Ethics Committee of the American Society for Reproductive Medicine.
27. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24:2917-2931.
28. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005, 83:1333-1338.